Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sodium bromide
- Development stage
- Phase 3
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Sodium bromide is an inorganic compound with the formula NaBr. It functions by enhancing the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) within the brain, inducing a calming effect on neuronal activity. It was widely used as an anticonvulsant and sedative in the late 19th and early 20th centuries. Though its use in human medicine has declined with newer medications, it continues to be used in veterinary medicine, particularly for treating seizure disorders in dogs.
- Brand names
- Sedoneural
- Other names
- NaBr
02
Targets
GABRR (GABA-A receptor subunit rho)GABA-B (Gamma-aminobutyric acid receptor type B)
Beyond the preview
Go deeper on sodium bromide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sodium bromide.